[Intranasal revaccination of children with live measles vaccine: development of local immunity].
Thirty-eight children aged 6-7 years were intranasally revaccinated against measles. Children without antimeasles antibodies in the serum responded to revaccination by their appearance in protective titers. In children with antibodies their titers increased (in 60%) on day 30 after intranasal revaccination. The efficacy of subcutaneous revaccination was the same. Intranasal, but not subcutaneous, revaccination resulted in appearance of nasopharyngeal anti-measles IgA. Intranasal method of revaccination against measles is convenient and safe and is recommended for clinical trials on a wide scale and for introduction into practice.
Liashenko
V A
VA
Iuminova
N V
NV
Krasnova
V P
VP
Glazkova
N V
NV
Svirina
V S
VS
D000281:Administration, Intranasal; D002648:Child; D006801:Humans; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000097:blood; D008457:Measles / Q000276:immunology / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology
D007070:Immunoglobulin A; D008458:Measles Vaccine
Intranazal'naia revaktsinatsiia deteĭ zhivoĭ korevoĭ vaktsinoĭ: razvitie mestnogo immuniteta.